References to Primary Literature
- MONCADA S, PALMER RMJ, HIGGS EA: Nitric oxide: physi-ology, pathophysiology and pharmacology. Pharmacol.Rev. (1991) 43: 109–142. Thorough review of pharmacological action of nitric oxide.
- CORBETT JA, TILTON RG, CHANG K, HASAN KS, IDO Y,WANG JL, SWEETLAND MA, LANCASTER JR, \WILLIAMSON JR, McDANIEL ML: Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dys-function. Diabetes (1992) 41: 552–556.
- BRUHWYLER J, CHLEIDE E, LIEGEOIS JF, CARREER F: Nitricoxide: A new messenger in the brain. Neurosci. Biobehav. Rev. (1993) 17: 373–384.
- MONCADA 5, IEGGS A: The L-arginine-nitric oxide path-way. N. Engl. J. Med. (1993) 329: 2002–2012.
- GARTHWAITE J: Glutamate, nitric oxide and cell-cell signalling in the nervous system. Trends Neurosci. (1991) 14: 60–67.
- STUEHR DJ, GROSS SS, SAKUMA I, LEVI R, NATHAN CF: Activated murine macrophages secrete a metabolite of arginkte with the bioactivity of endothelium-derived relaxing factor and the chemical reactivity of nitric oxide. J. Exp. Med. (1989) 169: 1011–1020.
- CORBETT JA, WANG JL, HUGHES JH, WOLF BA, SWEET LAND MA, LANCASTER JR, MCDANIEL ML: Nitric oxide and cyclic GMP formation induced by interleukin 1 fl in islets of Langerhans. Evidence for an effector role of nitric oxide in islet dysfunction. Biochem.J. (1992) 287: 229–235.
- SZABO C, MITCHELL JA, THIEMERMANN C, VANE JR: Nitricoxide-mediated hyporeactivity to noradrenaline pre-cedes the induction of nitric oxide synthase in endo-toxin shock. Br. J. Pharmacot (1993) 108: 786–792.
- DAWSON VL, DAWSON TM, LONDON ED, BREDT DS,SNYDER SH: Nitric oxide mediates glutamate neuro-toxicity in primary cortical cultures. Proc. Natl. Acad. Sci. USA (1991) 88: 6368–6371.
- ROGERS NE, IGNARRO LJ: Constitutive nitric oxide syn-thase from cerebellum is reversibly inhibited by nitric oxide formed from L-arginine. Biochem. Biophys. Res. Commun. (1992) 189: 242–249.
- GRISCAVAGE JM, ROGERS NE, SHERMAN MP, IGNARRO LJ:Inducible nitric oxide synthase from a rat alveolar macrophage cell line is inhibited by nitric oxide. J. immuna (1993) 151: 6329–6337.
- VALIANCE P, LEONE A, CALVER A, COLLIER), MONCADAS: Accumulation of an endogenous inhibitor of nitricoxide synthesis in chronic renal failure. Lancet (1992) 339: 572–575. First report of the presence of an endogenous NOS inhibitor.
- FICICLING S, LEONE A, NUSSEY A, VALIANCE P, WHITLEY G: Synthesis of NG;NG-dimethylarginine by human cells. Endothelium (1993) 1: 137–140.
- McALL1STER RJ, WHITLEY G, VALIANCE P: Effects of guanidino und uremic compounds on nitric oxide pathways. Kidney Int. (1994) 45: 737–742.
- YANG X, CAI B, SCIACCA RR, CANNON PJ: Inhibition ofinducible nitric oxide synthase in macrophages by oxidized low-density lipoproteins. Circ. Res. (1994) 74: 318–328.
- PALMER RMJ, ASTHON DS, MONCADA S: Vascular endo-thelial cells synthesize nitric oxide from L-arginine. Nature (1988) 333: 664–666.
- WHITTEN JP, McDONALD IA: Inhibition of nitric oxidebiosynthesis. Curr. Opin. Ther. Patents (1992) 2: 713–726.
- McCALL TB, FEELISCH M, PALMER RMJ, MONCADA S:
- •Identification of N-iminoethyl-L-ornithine as an irre-versible inhibitor of nitric oxide synthase in phagocytic cells. Br. J. Pharmacol. (1991) 102: 234–238.
- Report of the first real selective inducible NOS inhibitor.
- LAMBERT LE, FRENCH JF, WHITTEN JP, BARON BM, MCDONALD IA: Characterization of cell selectivity of two novel inhibitors of nitric oxide synthesis. Eur. Pharmacol. (1992) 216: 131–134.
- NARAYANAN K, GRIFFITH OW: Synthesis of L-thiocitrilline, L-homothiocitrulline and S-methyl-L- thiocitrealline: a new class of potent nitric oxide synthase inhibitors. J. Med. Chem. (1994) 37: 885–887. Interesting design of new NOS inhibitors using information on the active site of the enzyme.
- NARAYANAN K, SPACK L, HAYWARD M, GRIFFITH OW:S-methyl-L-thiodtrulline: a potent inhibitor of nitric oxide synthase with strong pressor activity in vivo. EASEL ?J. (1994) 8: A360.
- COWART M, ICERWIN JF, KOHLHAAS KL, KOWALUK EA,ALEXANDER KM: Synthesis of phosphorus-containing amino acid analogs as inhibitors of nitric oxide syn-thase. 24th National Medicinal Chemistry Symposium. Salt Lake City, Utah. (1994). Abstr. 40.
- MAY RC, KELLY RA, MITCH WE: Pathophysiology of uremia, in the kidney, Brenner BM, Rector FC (Eds.), (5th ed. ), Philadelphia, Saunders, (1991), 1997–2018.
- BROWNLEE M, VLASSARA H, KOONEY A, ULRICH P, CERAMI A: Aminoguankline prevents diabetes-induced arterial wall protein cross-linking. Science (1986) 232: 1629–1632.
- HASAN K, HEESEN BJ, CORBETT JA, McDANIEL ML, CHANG K, ALLISON W, WOLFFENBUTTEL BHR, WILLIAMSON JR, TILTON RG: Inhibition of nitric oxide formation by guanidines. Eur. J. Pharmacol. (1993) 249: 101–106.
- SCHOTTHarr CA, VETROVSKY P, STOCLET JC: Cationic amino acids inhibit the effects of L-arginine in rat aorta ex-posed to lipopolysaccharide. Eur. J. Pharmacol. (1993) 236: 155–157.
- MOORE PK, WALLACE P, GAFFEN Z, HART SL, BABBEDGE
- •RC: 7-nitro indazole, an inhibitor of nitric oxide syn-thase, exhibits antinociceptive activity in the mouse without increasing blood pressure. Br. J. Pharmacol. (1993) 108: 296–297. First report of heterocyclic based NOS inhibitors.
- BABBEDGE RC, BLAND-WARD SL, HART SL, MOORE PK:Inhibition of rat cerebellar nitric oxide synthase by 7-nitro indazole and related substituted indazoles. Br.J. Pharmacol. (1993) 110: 225–228.
- DWYER MA, BREDT DS, SNYDER SH: Nitric oxide syn-thase: irreversible inhibition by L-NG-nitro arginine in brainin vitro and in vivo. Biochem. Biophys. Res. Commun. (1991) 176: 1136–1141.
- MOORE PK, OLUYOMI AO, BABBEDGE RC, WALLACE P,HART SL: L-N6-nitro arginine methyl ester exhibits an-tinociceptive activity in the mouse. Br. J. Pharmacol. (1991) 102: 198–202.
- MOORE PK, WALLACE P, GAFFEN Z, HART SL, BABBEDGERC: Characterization of novel nitric oxide synthase Inhibitor 7-nitro indazole and related indazoies: anti-nociceptive and cardiovascular effects. Br. J. Pharmacol. (1993) 110: 219–224.
- MEDHURST AD, GREENLEES C, PARSONS AA, SMITH SJ:Nitric oxide synthase inhibitors 7- and 6-nitroindazole relax smooth muscle in vitro. Eur. J. Pharmacol. (1994) 256: R5–R6.
- HArrom R, INOUE R, SASE K, EIZAWA H, KOSUGA K, AOYAMA T, MASAYASU H, KAWAI C, SASAYAMA S, YUI Y: Preferential inhibition of inducible nitric oxide syn-thase by ebselen. Eur.J. Pharmacol. (1994) 267: R1–R2.
- SZABO C, THIEMERMANN C, VANE JR: Dihydropyridine antagonists and agonists of calcium channels inhibit the induction of nitric oxide synthase by endotoxin in cultured macrophages. Biochem. Biophys. Res. Commun. (1993) 196: 825–828.
- SZABO C, THIEMERMANN C, C(7U CC, VANE JR: Dilly-dropyridine calcium channel modulators inhibit the Induction of NO synthase and prevent the inhibition of cellular respiration caused by endotoxin in J774. 2 macrophages. Br. J. Pharmacol. (1994) 112: 419P.
- ZINGARELLI B, CARNUCCIO R, DI ROSA M: Cloricromene inhibks the induction of nitric oxide synthase. Eur. J. Pharmacol. (1993) 243: 107–111.
- HI) j, LEE JH, EL-FAKAHANY EE: Inhibition of neuralnitric oxide synthase by antipsychotic drugs. Psycho-pharmacology (1994) 114: 161–166.
- COHEN J, SILVA A: NO inhibitors and septic shock. Lancet(1992) 339: 751.
References to Patent Literature
- US DEPT OF HEALTH & HUMAN SERVICES, W09305775.
- WELLCOME FOUNDATION, W09313055.
- CORNELL RESEARCH FOUNDATION, US5273875.
- CORNELL RESEARCH FOUNDATION, W09324126.
- WASHINGTON UNIVERSITY, EP–547558–A.
- WASHINGTON UNIVERSITY, US5246970.
- WASHINGTON UNIVERSITY, EP–558468–A.
- WASHINGTON UNIVERSITY, US5317040.
- WELLCOME FOUNDATION, W09412165.
- CORNELL RESEARCH FOUNDATION, W09305780.
- ABBOTT, W09412163.
- WELLCOME FOUNDATION, W09414780.
- UNIVERSITY OF TEXAS, W09300893.
- UNIVERSITY OF TEXAS, W09324122.
- SOC CONSEILS RECH APPL SCI, DE4244539.